On April 25, Henan Lingrui Pharmaceutical Co.Ltd(600285) disclosed the annual report of 2021 and the first quarterly report of 2022. In 2021, Henan Lingrui Pharmaceutical Co.Ltd(600285) achieved an operating revenue of 2.69 billion yuan, a year-on-year increase of 15.52%; The net profit attributable to shareholders of listed companies was 360 million yuan, up 11.08% year-on-year.
Henan Lingrui Pharmaceutical Co.Ltd(600285) plans to distribute a cash dividend of 0.50 yuan (including tax) to all shareholders per share, and it is expected to distribute a cash dividend of 280 million yuan (including tax). In the first quarter of this year, Henan Lingrui Pharmaceutical Co.Ltd(600285) operating performance continued to grow. The revenue was 682 million yuan, a year-on-year increase of 15.73%; The net profit attributable to the parent company was 130 million yuan, a year-on-year increase of 35.41%. For the performance growth, Henan Lingrui Pharmaceutical Co.Ltd(600285) said that it was mainly due to the increase of sales revenue, the decrease of sales expense rate and the increase of government subsidies.
During the “14th five year plan” period, the company will continue to focus on the medical and health industry, adhere to the green, innovative and pragmatic development concept, strengthen the advantages of traditional Chinese medicine, highlight the orthopedic brand, actively cultivate a new development model with intelligent manufacturing, intelligent circulation and intelligent health as the core business sector, and promote the expansion of enterprise scale and the optimization of industrial structure. Build a leading brand of Chinese topical preparations and strive to be a leading enterprise in the production of orthopedic and cardio cerebrovascular drugs. At the same time, the company accelerated the progress of national market development, newly developed more than 7800 hospitals at all levels throughout the year, the sales revenue of Shenqi Jiangtang Capsule and Danlu Tongdu tablet exceeded 100 million yuan, and the market share of Peiyuan Tongnao capsule maintained a stable growth.
